Rocket Pharmaceuticals (RCKT) Stock
Gene therapy developer for rare inherited diseases. Here's the price, business snapshot, and what's worth knowing about Rocket Pharmaceuticals in October 2026.
Rocket Pharmaceuticals (RCKT) is a small‑cap, clinical‑stage biotechnology company focused on developing gene therapies for rare paediatric and adult inherited diseases, notably in haematology and metabolic disorders. Investors should know the company is pipeline‑driven — value typically hinges on clinical trial readouts, regulatory decisions and potential partnerships or licensing deals rather than current revenues. As a development company, Rocket carries higher risk: trial failures, delays, manufacturing challenges and funding needs can materially affect the share price. Conversely, successful phase results or regulatory approvals can be transformative. The company’s modest market capitalisation reflects its early‑stage profile and sensitivity to news flow; it's important to review cash runway, trial timelines and comparator data. For those considering exposure, Rocket may suit investors willing to accept volatility for potential upside from clinical progress, but it is not appropriate for those seeking steady income or low volatility. This is general information, not personalised investment advice.
Rocket Pharmaceuticals (RCKT) Stock Forecast
Analyst price target, next 12 months
$26.80
+947.0% vs today's $2.56
Price range over the last 12 months
Close to its 12-month low
Analysts covering Rocket Pharmaceuticals have a consensus 12-month target of $26.80, above the current price of $2.56.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 16 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Rocket Pharmaceuticals' stock, with a target price of $26.8, suggesting significant potential for growth.
Financial Health
Rocket Pharmaceuticals is showing solid financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Progress Watch
Clinical readouts are primary value drivers; positive trial data can change valuation quickly, though outcomes are uncertain and timelines may shift.
Gene‑therapy Focus
Specialises in gene therapies for rare inherited diseases, an area with high scientific promise and distinct regulatory and manufacturing challenges.
Partnerships And Catalysts
Collaborations or licensing deals can de‑risk programmes and provide funding, but prospective investors should weigh news‑driven volatility and financing needs.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
